Agenus Abandons Late-Line CRC Signal, Bets $340M on Unproven Neoadjuvant Leap

Agenus Pivots to Neoadjuvant Colon Cancer with $340M Funding

Agenus has secured $340 million in private funding to strategically shift its clinical development. The company will cease financial support for an ongoing late-stage trial of its immunotherapy combination, BOT+BAL, in late-line colorectal cancer. Instead, the new capital will back a registrational Phase 3 study evaluating the same regimen in the neoadjuvant setting for certain colon cancers, a market Agenus estimates represents an annual sales opportunity exceeding $7 billion. This financial move, supported by investors including RA Capital Management and TCGX, led to a doubling of company shares in early Monday trading and aims to sustain operations through an interim readout.

• Agenus successfully raised $340 million through an oversubscribed private placement, with key investments from RA Capital Management, TCGX, and other entities. This significant capital infusion is intended to provide the company with financial runway to operate through an interim readout of its newly prioritized clinical trial.
• The company is discontinuing its financial backing for a late-stage clinical trial evaluating the BOT+BAL immunotherapy combination in patients with late-line colorectal cancer. This decision marks a strategic pivot away from a previously ongoing program to reallocate resources towards a new, high-potential area.
• Agenus will now direct its new funding towards a registrational Phase 3 study investigating the BOT+BAL regimen in the neoadjuvant, or pre-surgery, setting for specific colon cancers. The company has identified this particular indication as a substantial commercial opportunity, projecting an annual sales potential of over $7 billion.

The Unmet Needs Driving Agenus's Colon Cancer Strategy

Colorectal cancer (CRC) continues to present a complex therapeutic landscape characterized by high rates of drug resistance, molecularly heterogeneous tumor populations, and persistently poor outcomes in advanced disease. Despite incremental progress across chemotherapy, targeted therapy, and immunotherapy, the 5-year survival rate for metastatic CRC remains approximately 14%, underscoring the substantial unmet need that continues to drive pipeline investment and strategic prioritization.

• Metastatic and treatment-refractory disease: The majority of patients with advanced or metastatic CRC derive limited benefit from existing regimens, including immune checkpoint blockades (ICBs), chemotherapy backbones, and targeted agents such as bevacizumab and cetuximab. Even with multimodal treatment, 5-year survival in patients experiencing recurrence or metastasis reaches only approximately 65%, highlighting the inadequacy of current standard-of-care approaches.

• Resistance across all therapeutic modalities: A significant proportion of patients develop primary or acquired resistance spanning chemotherapy, targeted therapy, radiotherapy, and immunotherapy. Resistance mechanisms are complex and incompletely characterized, with epithelial-mesenchymal plasticity (EMP) and hybrid EMT states identified as key drivers of phenotypic flexibility and therapeutic escape. Irinotecan resistance represents a specific challenge, with CDK7 and Midkine (MDK) emerging as targets to restore sensitivity.

• Molecularly defined subpopulations with distinct needs: Several genomically characterized subgroups carry specific unmet needs: KRAS G12C-mutated tumors (3–4% of refractory CRC) exhibit only moderate responses to available inhibitors with rapid resistance onset; BRAF V600E-mutated tumors require targeted first-line combination strategies, as demonstrated by the BREAKWATER study; HER2-positive tumors represent an emerging target class; and MSI-H/dMMR tumors, while responsive to checkpoint inhibitors, constitute a therapeutically distinct minority requiring tailored management.

• Absence of predictive biomarkers for chemotherapy response: Wide variability in tumor response and adverse reactions to chemotherapy creates a critical gap in treatment individualization. The lack of validated predictive biomarkers to guide chemotherapeutic selection remains an acute unmet need, with efforts such as NETs-score development (using LASSO Cox regression) representing early progress toward stratifying patients for chemotherapy and anti-CTLA-4/PD-L1 responsiveness.

• Low immunotherapy response rates in microsatellite-stable disease: Only a small proportion of GI cancer patients respond to PD-1/PD-L1 blockade, with the majority of CRC cases being microsatellite-stable (MSS) and therefore largely refractory to checkpoint inhibition. This drives an urgent need for novel immunologic and combination strategies capable of converting immunologically "cold" tumors.

• Late-stage diagnosis and systemic treatment access disparities: Late detection and high tumor heterogeneity continue to limit treatment efficacy across conventional modalities. In underserved populations — including a West Bank Palestinian cohort in which 63.1% of patients presented at stage IV and 41.3% died shortly after diagnosis — access to palliative care, targeted therapy, and individualized treatment protocols remains critically limited, pointing to both clinical and structural unmet needs.

BOT+BAL's Safety Profile for Neoadjuvant Colon Cancer

Published safety and tolerability data for the BOT+BAL combination have been evaluated across multiple tumor types, consistently demonstrating a manageable adverse event profile without treatment-related deaths or unexpected immune-mediated safety signals. Diarrhea/colitis emerges as the predominant treatment-related adverse event (TRAE) across indications, while the overall toxicity profile is qualitatively distinct from cytotoxic and antiangiogenic regimens.

• Microsatellite-Stable Metastatic Colorectal Cancer (MSS mCRC; n=148): TRAEs were reported in 89% of patients (131/148), with the most common being fatigue (35%, 52/148), diarrhea (32%, 47/148), and pyrexia (24%, 36/148). No grade 5 TRAEs were reported, and the discontinuation rate due to TRAEs was 12% (18/148). The toxicity profile was qualitatively distinct from other regimens associated with hematologic toxicity, nausea, hypertension, and dermatological effects. No new immune-mediated safety signals were identified.

• Advanced Sarcomas (n=64): All treated patients were evaluable for safety. The most common TRAE was diarrhea/colitis, occurring in 35.9% of patients, with grade 3 events in 6.3%. No grade 4 or 5 TRAEs were reported, supporting a manageable safety profile in a heavily pretreated population.

• Treatment-Refractory Ovarian Cancer (n=44): With a median of 3 prior lines of therapy and a median follow-up of 9.6 months (range: 0.6–36.6), the most common TRAE was diarrhea/colitis (43%; 16% grade 3). No treatment-related deaths were reported, and toxicities were characterized as manageable and reversible.

• Hepatocellular Carcinoma (HCC; n=19): Sixty-eight percent of patients (13/19) experienced any-grade immune-mediated TRAEs, with 37% (7/19) reaching grade 3. The most frequent immune-mediated TRAEs were diarrhea/colitis (37% [7/19]; 16% grade 3 [3/19]), hepatitis (21% [4/19]; 16% grade 3 [3/19]), and dermatologic events (21% [4/19]; 5% grade 3 [1/19]). No treatment-related deaths were observed, and no safety signals outside the established class profile were identified, including in patients previously treated with immunotherapy.

Agenus's Pivot and the Evolving Colon Cancer Landscape

Over the past decade, the colon cancer treatment landscape has undergone meaningful evolution across surgical, systemic, and multimodal domains, with published data reflecting incremental but measurable gains in outcomes. Population-level analyses spanning 2005–2019 document a shift toward minimally invasive surgery, with laparoscopic approaches increasing from 45.8% to 53.1% and robotic surgery rising from 2.9% to 12.7%. These changes have corresponded with improvements in surgical quality metrics — positive resection margins decreased from 7.2% to 6%, median lymph node yield increased from 14 to 16, and postoperative length of stay fell by two days. Perioperative mortality has similarly improved, with 30-day mortality declining from 3.9% to 2.8% and 90-day mortality from 7.1% to 5.0%. Mean 5-year overall survival increased modestly from 42.1 to 43.6 months — a notable achievement given the simultaneous rise in stage IV disease presentation from 27.9% to 47.9% over the same period.

Systemic therapy has evolved from a predominantly chemotherapy-centric paradigm toward an increasingly biomarker-driven framework. Immunotherapy utilization increased from 0.3% to 7.6% between 2005 and 2019, though meaningful responses remain confined to a minority of patients, largely those with mismatch repair-deficient tumors. For mismatch repair-proficient metastatic disease, phase I/Ib data from the regorafenib plus nivolumab combination (NCT03712943) using the Xerna™ TME Panel identified biomarker-positive patients with longer median PFS (7.9 vs. 4.1 months) and OS (15.75 vs. 11.9 months), though statistical significance was not reached. In the adjuvant setting, a key practice-changing development has been the reduction of CAPOX duration from 6 to 3 months in stage II and low-risk stage III disease, with comparable OS (HR 0.89; 95% CI 0.66–1.20) and superior patient-reported outcomes, including lower neuropathy rates (26.2% vs. 16.5%) and improved quality of life scores. For advanced inoperable disease, the current standard encompasses a short induction phase of 6–8 cycles followed by maintenance with biological agents stratified by RAS mutation status, with triplet regimens now emerging as first-line options.

Emerging data have also highlighted persistent structural challenges that constrain the translation of therapeutic advances into population-level benefit. Circulating tumor DNA (ctDNA) is gaining traction as a predictive biomarker; a prospective study of 96 patients demonstrated that a greater than 20% reduction in ctDNA by cycle 3 of FOLFOX was associated with treatment response (OR 4.12; 95% CI 1.76–9.67; P = 0.001), with an AUC of 0.84 for predicting chemoresistance — underscoring the unmet need for validated biomarkers to guide treatment selection. Treatment disparities remain a significant concern: non-Hispanic Black and Hispanic patients face substantially higher rates of treatment delays compared to non-Hispanic White patients, with these delays accounting for 23.6% and 56.7% of the observed survival differences, respectively. In Brazil, over 50% of patients across all clinical stages initiated treatment beyond the legally mandated 60-day threshold. Taken together, the colon cancer landscape reflects a field advancing on multiple fronts — surgical precision, treatment de-escalation, and biomarker integration — while confronting entrenched inequities in access and care delivery.

Agenus' Bold Pivot: Targeting Neoadjuvant Colon Cancer with BOT+BAL

The recent strategic pivot by Agenus, backed by a significant $340 million private funding round, marks a pivotal moment for the immunotherapy combination of botensilimab (BOT) and balstilimab (BAL). By shifting focus from late-line metastatic colorectal cancer (mCRC) to the neoadjuvant setting for certain colon cancers, the company is targeting a substantial $7 billion annual sales opportunity and addressing a critical unmet need.

Colorectal cancers that are mismatch repair proficient/microsatellite stable (pMMR/MSS) have historically been resistant to conventional immune checkpoint inhibitors, presenting a significant challenge for clinicians. However, BOT, an Fc-enhanced anti-CTLA-4 antibody, combined with BAL, an anti-PD-1 antibody, has shown promising activity. Early neoadjuvant studies in pMMR/MSS colon and rectal cancer have reported 'exceptional responses' and a unique 'inside-out' tumor regression pattern, suggesting a novel mechanism of action for BOT as an innate-adaptive immune activator. This early evidence points to the potential for this combination to induce significant immune-enriched states even in these typically 'cold' tumors, offering a new therapeutic avenue.

This strategic move, while promising, comes with inherent considerations. While early data are encouraging, the 'exceptional responses' were observed in a small patient cohort. The efficacy of BOT+BAL in a large, randomized Phase 3 neoadjuvant trial for pMMR/MSS colon cancer still requires robust confirmation. Furthermore, identifying specific biomarkers to predict response will be crucial. The literature suggests that a better understanding of disease characteristics and molecular biology is warranted for optimal patient selection, which could impact the overall success of a broad trial. As with other immune checkpoint inhibitor combinations, immune-mediated adverse events, such as diarrhea/colitis and hepatitis, are a known risk. Managing these toxicities effectively in a neoadjuvant population, where patients might otherwise be candidates for curative surgery, will be paramount.

Should the registrational Phase 3 trial confirm these early signals, BOT+BAL could redefine the standard of care in neoadjuvant pMMR/MSS colon cancer, potentially sparing patients from chemotherapy and improving long-term outcomes. This development highlights the ongoing evolution of immunotherapy, pushing its boundaries into earlier disease stages and historically challenging tumor subtypes.